Lifetime Achievements Awards 2026
The Lifetime Achievement Awards are a heartfelt tribute to the unwavering dedication of sarcoma specialists and patient representatives who have made a lasting impact on the sarcoma community. SPAGN proudly acknowledges and honors their outstanding contributions to sarcoma research and patient advocacy, their passion, perseverance, and unwavering commitment to making a difference. Through their work in research and advocacy, they have brought hope, inspired meaningful change, and helped shape a better future for everyone affected by sarcoma.
2026 Lifetime Achievement Award Recipients
Helga Meier-Schnorf (Switzerland) - Fritz Eichenberger on her behalf
Helga Meier-Schnorf is a pioneering sarcoma patient advocate with over 25 years of dedicated service in the field of GIST. As co-founder of one of the first sarcoma patient organizations in Switzerland, she has been instrumental in establishing patient support structures and advocating for patient needs at both national and European levels. Through her long-standing leadership, she has raised awareness, empowered patients, and ensured that the patient voice is central in research, policy, and care.
Markus Wartenberg (Germany)
Markus Wartenberg is a committed sarcoma patient advocate for more than 20 years and a key contributor to building and uniting patient communities in Germany and internationally. As a long-standing representative in national and global advocacy networks, including SPAGN, he has fostered collaboration across organisations, empowered patients, and strengthened the collective voice of the sarcoma community. His leadership has helped ensure that patient perspectives are central in research, policy, and care.
Peter Reichardt (Germany)
Prof. Dr. Peter Reichardt is an internationally renowned medical oncologist with expertise in sarcomas and GIST. Over the years, he has been a steadfast partner to the patient community, working closely with SPAGN and German sarcoma patient organisations to ensure that patient perspectives are central to research, clinical care, and advocacy initiatives. Through his long-term engagement, he has strengthened the dialogue between clinicians and patients, fostered multidisciplinary care, and supported patient-centered approaches that have improved outcomes and quality of life worldwide.
Heikki Joensuu (Finland)
Prof. Dr. Heikki Joensuu is an internationally recognized oncologist and researcher whose work has transformed the treatment of sarcomas, particularly GIST. He played a leading role in the clinical development of imatinib, a breakthrough therapy that turned a once untreatable disease into a manageable condition. Beyond his clinical achievements, he has consistently engaged with patient communities to ensure research and care advancements align with real patient needs, improving outcomes worldwide.